Mastercard is moving toward faster investigations and broader measurement of merchant risk. Here is what card-not-present and high-risk businesses should know about the new 72-hour standard, GMAP, and protecting their processing relationship.

The FDA's July 2026 review of seven peptides could have far-reaching implications beyond healthcare. As regulators evaluate potential changes to compounding eligibility, payment processors, banks, and merchants are watching closely. Learn how increased regulatory clarity may affect merchant account approvals, underwriting standards, banking relationships, and payment processing opportunities for businesses operating in the peptide industry.